One area of the share market that has been performing very positively over the last decade has been the healthcare sector.
Since this time in 2010, the S&P/ASX 200 Health Care index has generated a return of 432% for investors.
This has been driven by increased demand, better technologies and treatments, and ageing populations.
Given how these tailwinds are likely to remain for the long term, it isn’t a surprise to see that healthcare shares are popular with ASX investors today.
But which healthcare shares should you buy? Here are two highly rated options:
Cochlear Limited (ASX: COH)
When it comes to shifting demographics, and particularly in respect to the growing number of over 65s, there are few companies that stand to benefit as much as Cochlear. It is the global developer, manufacturer, and distributor of cochlear implantable devices for the hearing impaired.
Late last month analysts at Macquarie put an outperform rating and $241.00 price target on Cochlear’s shares. They have been pleased with both its market share gains and the positive opinion of its products by audiologists. This bodes well for its recovery from the pandemic and future growth.
CSL Limited (ASX: CSL)
CSL is one of the world’s leading biotherapeutics companies. It has been a consistently strong performer over the last decade thanks to acquisitions, its research and development activities, growing plasma collection network, and its leading therapies. The latter includes therapies such as Privigen, Hizentra, Idelvion, and Afstyla.
One broker that is confident that this strong form can continue is UBS. Last week the investment bank retained its buy rating and $346.00 price target on the company’s shares. While it notes that plasma collection conditions are tough in some markets because of COVID-19, it remains positive on its outlook. Especially given how it has a range of options to mitigate this headwind.
Man who said buy Kogan shares at $3.63 says buy these 3 ASX stocks now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
Find out the names of our 3 Post COVID Stocks – For FREE!
*Returns as of 6/8/2020
More reading
- Top brokers name 3 ASX shares to buy today
- ASX 200 Weekly Wrap: ASX 200 has another shocker as US election approaches
- Top ASX shares to buy in November 2020
- 4 outstanding ASX 200 shares to buy with $4,000
- Where to invest $100,000 into ASX shares in November
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. and CSL Ltd. The Motley Fool Australia has recommended Cochlear Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post 2 ASX healthcare shares to buy today appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/2IcY1bs
Leave a Reply